Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.
Bullous pemphigoid
biologics
comorbidity
dupilumab
immunosuppressant
real-world study
severity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
02
2023
accepted:
04
07
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Bullous pemphigoid (BP) is a common subepidermal bullous disorder that lacks adequate treatment alternatives. Dupilumab, an anti-interleukin (IL) 4 receptor α antibody blocking Th2 molecules IL-4 and 13, has been used off-label and shown to be effective in refractory BP cases. BP patients with various disease severities and comorbidities were included in this case series. All patients received dupilumab alone or in combination with immunosuppressants in a real-world setting. Complete remission (CR) was defined as the absence of pruritus symptoms and previous BP eruptions, with only hyperpigmentation patches and without newly occurring lesions for at least 4 weeks. Disease relapse was classified as the appearance of three or more new lesions within 1 month or at least one large urticarial or eczematous lesion that did not resolve within a week. Ten individuals were enrolled in this case series. Pruritus symptoms and BP eruptions improved significantly in nine patients (90%). Seven patients (70%) attained CR, including all mild-to-moderate (100%) cases and three of six (50%) severe BP cases. At the dupilumab monotherapy stage, eosinophilia was observed in two severe cases. One patient out of seven (14.3%) relapsed after 1 year of follow-up after CR. Treatment of BP with diverse comorbidities with anti-IL-4 receptor α antibody provides further credentials to a prospective randomized study. More impressive efficacy and safety profiles were observed in patients with mild-to-moderate disease after 1 year of follow-up. Eosinophilia may occur in patients receiving dupilumab monotherapy.
Sections du résumé
Background
Bullous pemphigoid (BP) is a common subepidermal bullous disorder that lacks adequate treatment alternatives. Dupilumab, an anti-interleukin (IL) 4 receptor α antibody blocking Th2 molecules IL-4 and 13, has been used off-label and shown to be effective in refractory BP cases.
Methods
BP patients with various disease severities and comorbidities were included in this case series. All patients received dupilumab alone or in combination with immunosuppressants in a real-world setting. Complete remission (CR) was defined as the absence of pruritus symptoms and previous BP eruptions, with only hyperpigmentation patches and without newly occurring lesions for at least 4 weeks. Disease relapse was classified as the appearance of three or more new lesions within 1 month or at least one large urticarial or eczematous lesion that did not resolve within a week.
Findings
Ten individuals were enrolled in this case series. Pruritus symptoms and BP eruptions improved significantly in nine patients (90%). Seven patients (70%) attained CR, including all mild-to-moderate (100%) cases and three of six (50%) severe BP cases. At the dupilumab monotherapy stage, eosinophilia was observed in two severe cases. One patient out of seven (14.3%) relapsed after 1 year of follow-up after CR.
Conclusion
Treatment of BP with diverse comorbidities with anti-IL-4 receptor α antibody provides further credentials to a prospective randomized study. More impressive efficacy and safety profiles were observed in patients with mild-to-moderate disease after 1 year of follow-up. Eosinophilia may occur in patients receiving dupilumab monotherapy.
Identifiants
pubmed: 37545503
doi: 10.3389/fimmu.2023.1165106
pmc: PMC10399451
doi:
Substances chimiques
dupilumab
420K487FSG
Immunosuppressive Agents
0
Interleukin-4 Receptor alpha Subunit
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165106Informations de copyright
Copyright © 2023 Wang, Shan, Li and Zuo.
Déclaration de conflit d'intérêts
Y-GZ served as a speaker for Sanofi, but this was not associated with this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Dermatol Ther. 2022 Apr;35(4):e15330
pubmed: 35080079
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Dermatol Ther. 2022 Jul;35(7):e15541
pubmed: 35478478
J Investig Allergol Clin Immunol. 2022 Apr 19;32(2):97-115
pubmed: 33661102
Br J Dermatol. 2012 Dec;167(6):1200-14
pubmed: 23121204
Dermatol Ther. 2022 Sep;35(9):e15727
pubmed: 35861645
Dermatol Ther. 2022 Aug;35(8):e15648
pubmed: 35715972
N Engl J Med. 2022 Dec 22;387(25):2317-2330
pubmed: 36546624
J Am Acad Dermatol. 2020 Jul;83(1):46-52
pubmed: 32179082
Br J Dermatol. 1999 Jun;140(6):1079-86
pubmed: 10354074
Br J Dermatol. 2021 Jun;184(6):1106-1112
pubmed: 33067805
Front Immunol. 2018 Feb 19;9:248
pubmed: 29520266
Acta Derm Venereol. 2018 Feb 7;98(2):284-286
pubmed: 29136264
JAMA Dermatol. 2017 Jan 1;153(1):30-38
pubmed: 27829102
Allergy. 2020 Mar;75(3):669-672
pubmed: 31230371
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e539-e542
pubmed: 35143077
Dermatol Online J. 2022 Mar 15;28(2):
pubmed: 35670683
Am J Clin Dermatol. 2019 Apr;20(2):209-216
pubmed: 30421306
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e394-e396
pubmed: 33594731
Dermatol Ther. 2020 Jul;33(4):e13721
pubmed: 32500934
JAAD Case Rep. 2022 Sep 23;29:149-151
pubmed: 36275873
Br J Dermatol. 2021 Jul;185(1):210-212
pubmed: 33657641
J Autoimmun. 2016 Sep;73:111-9
pubmed: 27377454
An Bras Dermatol. 2019 Apr;94(2 Suppl 1):33-47
pubmed: 31166405
Front Med (Lausanne). 2018 Jul 10;5:201
pubmed: 30042946
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1778-1782
pubmed: 27357866
Dermatol Ther. 2022 Nov;35(11):e15890
pubmed: 36181411
Br J Dermatol. 2012 May;166(5):1140-2
pubmed: 22098309
Dermatol Ther. 2022 Aug;35(8):e15623
pubmed: 35669992
Int J Dermatol. 2023 Mar;62(3):e144-e146
pubmed: 36214412
J Invest Dermatol. 2001 Nov;117(5):1097-102
pubmed: 11710918
Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):577-9
pubmed: 27297272
Autoimmun Rev. 2020 Nov;19(11):102661
pubmed: 32942041
J Allergy Clin Immunol. 2009 Mar;123(3):704-5
pubmed: 19152970
J Am Acad Dermatol. 2014 Sep;71(3):468-74
pubmed: 24954907
Front Immunol. 2021 Oct 14;12:738907
pubmed: 34721404
J Dtsch Dermatol Ges. 2015 Jul;13(7):713-27
pubmed: 26110729
J Am Acad Dermatol. 2019 Jul;81(1):179-186
pubmed: 30923002
JAMA Dermatol. 2022 Jun 1;158(6):641-649
pubmed: 35507334
J Am Acad Dermatol. 2016 Apr;74(4):700-8.e3
pubmed: 26851830
J Dermatol Sci. 2002 Nov;30(2):116-28
pubmed: 12413767
J Am Acad Dermatol. 2020 May;82(5):1237-1239
pubmed: 31738960
Front Med. 2019 Oct;13(5):556-563
pubmed: 30604167
Ann Dermatol Venereol. 2022 Jun;149(2):81-91
pubmed: 34702559
Arch Dermatol. 2012 Nov;148(11):1241-3
pubmed: 23165827
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e135-e137
pubmed: 36268775
Dermatol Ther. 2020 Nov;33(6):e13958
pubmed: 32621642
Dermatol Ther. 2022 Feb;35(2):e15243
pubmed: 34854196
Dermatol Ther (Heidelb). 2023 Jan;13(1):7-12
pubmed: 36355314
J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300
pubmed: 25482871
J Dermatol. 2022 Sep;49(9):845-850
pubmed: 35538742
J Am Acad Dermatol. 2020 Jul;83(1):37-38
pubmed: 32179081
J Autoimmun. 2019 Jan;96:104-112
pubmed: 30219389